Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Company profile
Ticker
NYXH
Exchange
Website
CEO
Olivier Taelman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NYXH stock data
Latest filings (excl ownership)
6-K
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
15 Apr 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
19 Mar 24
6-K
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
5 Mar 24
6-K
Nyxoah Announces 2024 Strategic Priorities
17 Jan 24
6-K
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023
9 Jan 24
6-K
Current report (foreign)
11 Dec 23
6-K
Nyxoah Reports Third Quarter 2023 Financial and Operating Results
8 Nov 23
6-K
Nyxoah Announces Partnership with ResMed in Germany
29 Sep 23
6-K
Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results
8 Aug 23
Latest ownership filings
SC 13G/A
TOGETHER PARTNERSHIP
14 Feb 24
SC 13G/A
Taub Robert
14 Feb 24
SC 13G/A
RESMED INC
6 Jul 23
SC 13G
RESMED INC
6 Apr 23
SC 13D/A
Cochlear Ltd
29 Mar 23
SC 13G
TOGETHER PARTNERSHIP
14 Feb 22
SC 13G
Taub Robert
11 Feb 22
SC 13G
Gilde Healthcare Holding B.V.
10 Feb 22
SC 13D
Cochlear Ltd
16 Jul 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
43.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 14 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 20.31 bn |
Total shares | 12.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cochlear | 5.09 mm | $34.62 mm |
Gilde Healthcare Holding B.V. | 3.15 mm | $0.00 |
RMD Resmed | 1.62 mm | $11.84 mm |
BLK Blackrock | 653.32 k | $5.23 bn |
Deerfield Management | 455.26 k | $3.65 bn |
Opaleye Management | 445.00 k | $3.56 bn |
AXAHF Axa | 217.00 k | $1.74 bn |
Sio Capital Management | 200.08 k | $1.60 bn |
Putnam Investments | 192.94 k | $1.58 bn |
FMR | 134.43 k | $1.10 bn |
News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
11 Apr 24
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
11 Apr 24
HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $22 Price Target
25 Mar 24
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
21 Mar 24
Press releases
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
11 Apr 24
Information on the total number of voting rights and shares
29 Mar 24
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation
25 Mar 24
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
5 Mar 24
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
29 Feb 24